{"id":70098,"date":"2026-07-16T16:28:18","date_gmt":"2026-07-16T08:28:18","guid":{"rendered":"https:\/\/flcube.com\/?p=70098"},"modified":"2026-07-16T16:28:18","modified_gmt":"2026-07-16T08:28:18","slug":"ascletis-pharma-selects-asc30_48-fdc-as-first-in-class-oral-dual-gipr-glp-1r-agonist-for-obesity","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70098","title":{"rendered":"Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR\/GLP-1R Agonist for Obesity"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Ascletis Pharma Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1672:HKG\">HKG: 1672<\/a>) announced today the selection of its <strong>fixed-dose combination (FDC)<\/strong> of <strong>ASC48<\/strong> (oral GIPR agonist) and <strong>ASC30<\/strong> (oral GLP-1R agonist) for clinical development as a potential <strong>first-in-class oral obesity therapy<\/strong>. The ASC30_48 FDC is designed for <strong>&#8220;one pill, once daily&#8221;<\/strong> administration, with an Investigational New Drug (IND) application expected to be submitted to the <strong>US FDA in Q4 2026<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-development-milestone-key-details\" class=\"wp-block-heading\">Development Milestone | Key Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Ascletis Pharma Inc. (HKG: 1672)<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>ASC30_48 FDC (ASC48 + ASC30)<\/td><\/tr><tr><td><strong>Regulatory Target<\/strong><\/td><td>US FDA<\/td><\/tr><tr><td><strong>IND Submission Timeline<\/strong><\/td><td>Q4 2026<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Obesity<\/td><\/tr><tr><td><strong>Dosing Regimen<\/strong><\/td><td>One pill, once daily<\/td><\/tr><tr><td><strong>Development Status<\/strong><\/td><td>Preclinical candidate selection completed<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 id=\"h-molecular-components\" class=\"wp-block-heading\">Molecular Components<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ASC48:<\/strong> Potential first-in-class oral small molecule GIPR (glucose-dependent insulinotropic polypeptide receptor) agonist<\/li>\n\n\n\n<li><strong>ASC30:<\/strong> Oral small molecule GLP-1R (glucagon-like peptide-1 receptor) agonist<\/li>\n\n\n\n<li><strong>Combination:<\/strong> Fixed-dose dual GIPR\/GLP-1R targeting<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First oral dual agonist combination in development<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-proprietary-technology-platform\" class=\"wp-block-heading\">Proprietary Technology Platform<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">ASC48 was developed using Ascletis&#8217; <strong>AI-structured-based drug discovery (AISBDD)<\/strong> technology:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AI-Driven Design:<\/strong> Leveraged artificial intelligence for molecular optimization<\/li>\n\n\n\n<li><strong>Structural Precision:<\/strong> Enhanced target specificity and pharmacokinetic properties<\/li>\n\n\n\n<li><strong>Proprietary Platform:<\/strong> Differentiates from traditional high-throughput screening approaches<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-preclinical-pharmacokinetic-profile\" class=\"wp-block-heading\">Preclinical Pharmacokinetic Profile<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">ASC48 demonstrated compelling drug-like properties supporting once-daily dosing:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oral Bioavailability:<\/strong> Excellent absorption following oral administration<\/li>\n\n\n\n<li><strong>Drug Exposure:<\/strong> High systemic exposure levels achieved<\/li>\n\n\n\n<li><strong>Half-life:<\/strong> Long elimination half-life suitable for once-daily regimen<\/li>\n\n\n\n<li><strong>Dosing Convenience:<\/strong> Single tablet formulation enables patient compliance<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-market-opportunity\" class=\"wp-block-heading\">Strategic Rationale &amp; Market Opportunity<\/h2>\n\n\n\n<h3 id=\"h-obesity-treatment-landscape\" class=\"wp-block-heading\">Obesity Treatment Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Size:<\/strong> Global obesity therapeutics market projected to exceed <strong>$100 billion by 2030<\/strong><\/li>\n\n\n\n<li><strong>Current Leaders:<\/strong> Injectable GLP-1\/GIP dual agonists (e.g., tirzepatide) demonstrating superior efficacy<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Oral alternatives to injectable therapies with comparable efficacy<\/li>\n\n\n\n<li><strong>Patient Preference:<\/strong> Strong demand for needle-free administration options<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-competitive-differentiation\" class=\"wp-block-heading\">Competitive Differentiation<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The ASC30_48 FDC offers several potential advantages:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First Oral Dual Agonist:<\/strong> Addresses significant gap vs. current injectable-only dual agonists<\/li>\n\n\n\n<li><strong>Convenience Factor:<\/strong> &#8220;One pill, once daily&#8221; vs. weekly injections<\/li>\n\n\n\n<li><strong>Cost Potential:<\/strong> Oral manufacturing typically less expensive than biologic production<\/li>\n\n\n\n<li><strong>Accessibility:<\/strong> Broader patient access without injection requirements<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-ai-driven-innovation\" class=\"wp-block-heading\">AI-Driven Innovation<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ascletis&#8217; AISBDD platform represents a <strong>next-generation drug discovery approach<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Accelerated Development:<\/strong> AI-enabled molecular design reduces discovery timelines<\/li>\n\n\n\n<li><strong>Enhanced Properties:<\/strong> Computational optimization of pharmacokinetic parameters<\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Strong patent protection around AI-designed molecules<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Success with ASC48 validates AISBDD for future pipeline candidates<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-development-timeline-amp-regulatory-strategy\" class=\"wp-block-heading\">Development Timeline &amp; Regulatory Strategy<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The company&#8217;s aggressive development timeline includes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Q4 2026:<\/strong> IND submission to US FDA<\/li>\n\n\n\n<li><strong>2027:<\/strong> Initiation of Phase 1 clinical trials<\/li>\n\n\n\n<li><strong>2028-2029:<\/strong> Phase 2 proof-of-concept studies<\/li>\n\n\n\n<li><strong>2030+:<\/strong> Potential Phase 3 development and regulatory submissions<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This timeline positions Ascletis to potentially become the <strong>first company to market an oral dual GIPR\/GLP-1R agonist<\/strong>, capitalizing on the massive commercial opportunity in obesity treatment while addressing key patient barriers to current therapies.<\/p>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">For Ascletis, the ASC30_48 FDC represents a <strong>transformative pipeline asset<\/strong> that could:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Establish the company as a leader in oral metabolic disease therapeutics<\/li>\n\n\n\n<li>Generate significant licensing or partnership opportunities with major pharma<\/li>\n\n\n\n<li>Validate the AISBDD platform for broader application across therapeutic areas<\/li>\n\n\n\n<li>Create substantial shareholder value through clinical and regulatory milestones<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The dual agonist approach leverages emerging scientific understanding that <strong>combined GIPR and GLP-1R activation<\/strong> provides superior weight loss efficacy compared to GLP-1R agonism alone, as demonstrated by the clinical success of injectable dual agonists.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory submissions, and market opportunities. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071500737_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026071500737_c.\"><\/object><a id=\"wp-block-file--media-743fbd8f-0185-40dd-82f9-f934548f9d4c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071500737_c.pdf\">2026071500737_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071500737_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-743fbd8f-0185-40dd-82f9-f934548f9d4c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ascletis Pharma Inc. (HKG: 1672) announced today the selection of its fixed-dose combination (FDC) of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[189,980,86],"class_list":["post-70098","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-ascletis-pharma","tag-hkg-1672","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR\/GLP-1R Agonist for Obesity - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ascletis Pharma Inc. (HKG: 1672) announced today the selection of its fixed-dose combination (FDC) of ASC48 (oral GIPR agonist) and ASC30 (oral GLP-1R agonist) for clinical development as a potential first-in-class oral obesity therapy. The ASC30_48 FDC is designed for &quot;one pill, once daily&quot; administration, with an Investigational New Drug (IND) application expected to be submitted to the US FDA in Q4 2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70098\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR\/GLP-1R Agonist for Obesity\" \/>\n<meta property=\"og:description\" content=\"Ascletis Pharma Inc. (HKG: 1672) announced today the selection of its fixed-dose combination (FDC) of ASC48 (oral GIPR agonist) and ASC30 (oral GLP-1R agonist) for clinical development as a potential first-in-class oral obesity therapy. The ASC30_48 FDC is designed for &quot;one pill, once daily&quot; administration, with an Investigational New Drug (IND) application expected to be submitted to the US FDA in Q4 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70098\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-16T08:28:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70098#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70098\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR\\\/GLP-1R Agonist for Obesity\",\"datePublished\":\"2026-07-16T08:28:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70098\"},\"wordCount\":576,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ascletis Pharma\",\"HKG: 1672\",\"Obesity\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70098#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70098\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70098\",\"name\":\"Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR\\\/GLP-1R Agonist for Obesity - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-16T08:28:18+00:00\",\"description\":\"Ascletis Pharma Inc. (HKG: 1672) announced today the selection of its fixed-dose combination (FDC) of ASC48 (oral GIPR agonist) and ASC30 (oral GLP-1R agonist) for clinical development as a potential first-in-class oral obesity therapy. The ASC30_48 FDC is designed for \\\"one pill, once daily\\\" administration, with an Investigational New Drug (IND) application expected to be submitted to the US FDA in Q4 2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70098#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70098\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70098#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR\\\/GLP-1R Agonist for Obesity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR\/GLP-1R Agonist for Obesity - Insight, China&#039;s Pharmaceutical Industry","description":"Ascletis Pharma Inc. (HKG: 1672) announced today the selection of its fixed-dose combination (FDC) of ASC48 (oral GIPR agonist) and ASC30 (oral GLP-1R agonist) for clinical development as a potential first-in-class oral obesity therapy. The ASC30_48 FDC is designed for \"one pill, once daily\" administration, with an Investigational New Drug (IND) application expected to be submitted to the US FDA in Q4 2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70098","og_locale":"en_US","og_type":"article","og_title":"Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR\/GLP-1R Agonist for Obesity","og_description":"Ascletis Pharma Inc. (HKG: 1672) announced today the selection of its fixed-dose combination (FDC) of ASC48 (oral GIPR agonist) and ASC30 (oral GLP-1R agonist) for clinical development as a potential first-in-class oral obesity therapy. The ASC30_48 FDC is designed for \"one pill, once daily\" administration, with an Investigational New Drug (IND) application expected to be submitted to the US FDA in Q4 2026.","og_url":"https:\/\/flcube.com\/?p=70098","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-16T08:28:18+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70098#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70098"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR\/GLP-1R Agonist for Obesity","datePublished":"2026-07-16T08:28:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70098"},"wordCount":576,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ascletis Pharma","HKG: 1672","Obesity"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70098#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70098","url":"https:\/\/flcube.com\/?p=70098","name":"Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR\/GLP-1R Agonist for Obesity - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-16T08:28:18+00:00","description":"Ascletis Pharma Inc. (HKG: 1672) announced today the selection of its fixed-dose combination (FDC) of ASC48 (oral GIPR agonist) and ASC30 (oral GLP-1R agonist) for clinical development as a potential first-in-class oral obesity therapy. The ASC30_48 FDC is designed for \"one pill, once daily\" administration, with an Investigational New Drug (IND) application expected to be submitted to the US FDA in Q4 2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70098#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70098"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70098#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR\/GLP-1R Agonist for Obesity"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70098","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70098"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70098\/revisions"}],"predecessor-version":[{"id":70100,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70098\/revisions\/70100"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70098"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70098"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70098"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}